DE60325551D1 - Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung - Google Patents

Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung

Info

Publication number
DE60325551D1
DE60325551D1 DE60325551T DE60325551T DE60325551D1 DE 60325551 D1 DE60325551 D1 DE 60325551D1 DE 60325551 T DE60325551 T DE 60325551T DE 60325551 T DE60325551 T DE 60325551T DE 60325551 D1 DE60325551 D1 DE 60325551D1
Authority
DE
Germany
Prior art keywords
hemmer
3beta
gsk
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325551T
Other languages
English (en)
Inventor
Patricia Ann Day-Lollini
Leyi Gong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60325551D1 publication Critical patent/DE60325551D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60325551T 2002-01-10 2003-01-07 Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung Expired - Lifetime DE60325551D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34805502P 2002-01-10 2002-01-10
PCT/EP2003/000049 WO2003057202A1 (en) 2002-01-10 2003-01-07 Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation

Publications (1)

Publication Number Publication Date
DE60325551D1 true DE60325551D1 (de) 2009-02-12

Family

ID=23366458

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325551T Expired - Lifetime DE60325551D1 (de) 2002-01-10 2003-01-07 Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung

Country Status (10)

Country Link
US (1) US7476676B2 (de)
EP (1) EP1465610B1 (de)
JP (1) JP4237066B2 (de)
CN (1) CN100409840C (de)
AR (1) AR038276A1 (de)
AU (1) AU2003235798A1 (de)
CA (1) CA2471565C (de)
DE (1) DE60325551D1 (de)
ES (1) ES2316756T3 (de)
WO (1) WO2003057202A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528805A1 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US20050064044A1 (en) * 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
JP5289769B2 (ja) 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
US7670742B2 (en) 2005-03-15 2010-03-02 Ricoh Company, Ltd. Recording material, toner, liquid developer and image forming method using the same
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1757607A1 (de) 2005-08-24 2007-02-28 Molisa GmbH N5-substituierte Benzo¬2,3|azepino¬4,5-b|indol-6-one zur Behandlung tropischer Krankheiten
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
US20100137330A1 (en) * 2007-03-08 2010-06-03 Ratan Bhat Use
EP2343291A1 (de) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren
RU2012135093A (ru) 2010-01-19 2014-03-10 Астразенека Аб Производные пиразина
US8884010B2 (en) * 2010-09-08 2014-11-11 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
WO2012035770A1 (ja) * 2010-09-15 2012-03-22 国立大学法人 新潟大学 グリコーゲンを含有する骨形成促進剤
EP2474541A1 (de) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren
EP3187495A1 (de) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN113248472B (zh) * 2020-02-12 2022-06-28 中国药科大学 抗骨质疏松化合物及其衍生物，药物组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
SK14082001A3 (sk) * 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
AU782878B2 (en) * 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CZ2003555A3 (en) * 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
KR100947185B1 (ko) * 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof

Also Published As

Publication number Publication date
WO2003057202A1 (en) 2003-07-17
JP4237066B2 (ja) 2009-03-11
CN100409840C (zh) 2008-08-13
AR038276A1 (es) 2005-01-12
CA2471565A1 (en) 2003-07-17
CN1703207A (zh) 2005-11-30
ES2316756T3 (es) 2009-04-16
WO2003057202A8 (en) 2003-12-11
AU2003235798A8 (en) 2003-07-24
CA2471565C (en) 2009-10-27
US20030176484A1 (en) 2003-09-18
EP1465610B1 (de) 2008-12-31
AU2003235798A1 (en) 2003-07-24
JP2005519056A (ja) 2005-06-30
US7476676B2 (en) 2009-01-13
EP1465610A1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
DE60325551D1 (de) Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
ITMI20042393A1 (it) Procedimento per la fabbricazione di un componente a semiconduttore nonche' un componente a semiconduttore in particolare un sensore a membrana
DE50207943D1 (de) Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE60236767D1 (de) Medizinische Verwendung eines TetrahydrotriazoloÄ4,3-aÜpyrazins
ITMI20020121A0 (it) Perfezionamenti in cashi per la respirazione artificiale senza l'ausilio di maschere
DE60233826D1 (de) Form zur herstellung von fasergussformteilen
DE60109579D1 (de) Stabilisierte kieselsäure und verfahren zur herstellung und verwendung derselben
EP1530449A4 (de) Künstliche hornhaut
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
FR2846545B1 (fr) Implant d'osteosynthese intramedullaire
DE60112431D1 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
FR2892920B1 (fr) Injecteur et cartouche de pliage d'implant ophtalmique
EP1637589A4 (de) Neue, von adultem gewebe abgeleitete stammzelle und deren verwendung
SE0203497L (sv) Anordning avsedd att ingå i framställning av kolfiberförstärkt tandprotes
AU2003254677A8 (en) Innervated artificial tissues and uses thereof
DE602004002231D1 (de) Knochenkontaktierendes Implantat mit stossdämpfenden Eigenschaften und Verfahren zu dessen Herstellung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
DE50209948D1 (de) Verwendung von Scopinester Derivaten zur Herstellung von Arzneimitteln
DE10242955B4 (de) Kunststoffaß und Verfahren zur Herstellung des Fasses
AT502793A5 (de) Grobkeramischer formkörper, verfahren zu dessen herstellung und verwendung
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
DE60328456D1 (de) Eine kontinuierliche zellinie zur herstellung von impfstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition